L
Luis F. Maia
Researcher at University of Porto
Publications - 41
Citations - 2616
Luis F. Maia is an academic researcher from University of Porto. The author has contributed to research in topics: Medicine & Transthyretin. The author has an hindex of 17, co-authored 31 publications receiving 2136 citations. Previous affiliations of Luis F. Maia include University of Tübingen & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Pierre Lozeron,Ole B. Suhr,Josep M. Campistol,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason Chan,Jeff Packman,Amy Wilson,Donna R. Grogan +16 more
TL;DR: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment.
Journal ArticleDOI
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
Mehtap Bacioglu,Luis F. Maia,Oliver Preische,Juliane Schelle,Juliane Schelle,Anja Apel,Stephan A. Kaeser,Manuel Schweighauser,Manuel Schweighauser,Timo Eninger,Timo Eninger,Marius Lambert,Marius Lambert,Andrea Pilotto,Andrea Pilotto,Derya R. Shimshek,Ulf Neumann,Philipp J. Kahle,Philipp J. Kahle,Matthias Staufenbiel,Matthias Staufenbiel,Manuela Neumann,Walter Maetzler,Walter Maetzler,Jens Kuhle,Mathias Jucker,Mathias Jucker +26 more
TL;DR: It is suggested that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases.
Journal ArticleDOI
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Ole B. Suhr,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason L. Chan,Jeff Packman,Donna R. Grogan +13 more
TL;DR: Tafamidis was well tolerated, with the reduced rate of neurologic deterioration sustained over 30 months, and slowed neurologic impairment in patients previously given placebo, but treatment benefits were greater when taf amidis was begun earlier.
Journal ArticleDOI
The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease
Veronica Hirsch-Reinshagen,Luis F. Maia,Braydon L. Burgess,Jean-Francois Blain,Kathryn E. Naus,Sean A. McIsaac,Pamela F. Parkinson,Jennifer Y. Chan,Gavin Tansley,Michael R. Hayden,Judes Poirier,William E. Van Nostrand,Cheryl L. Wellington +12 more
TL;DR: It is reported that the deficiency of ABCA1 does not affect soluble or guanidine-extractable Aβ levels in Tg-SwDI/B or amyloid precursor protein/presenilin 1 (APP/PS1) mice, but rather is associated with a dramatic reduction in soluble apoE levels in brain.
Journal ArticleDOI
Does SARS-Cov-2 invade the brain? Translational lessons from animal models.
TL;DR: The current knowledge from models of previous CoV infections and their potential relevance to COVID‐19 are described and discussed.